Evelo Biosciences

About

Evelo Biosciences develops oral biologics with systemic therapeutic effects.

Cambridge,Massachusetts,United States
101 - 250
http://evelobio.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: $45M
Industries: Biotechnology,Health Care,Medical,Therapeutics
Founded date: Jan 1, 2015
Number Of Employee: 101 - 250
Operating Status: Active
Stock Symbol: nasdaq:EVLO
Legal Name: Evelo Biosciences, Inc.

Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, Evelo can improve the speed, cost and success of drug discovery and development. Evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. Evelo Biosciences was conceived and created within VentureLabs®, Flagship Pioneering’s institutional innovation foundry, and launched by Flagship in 2015.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

7

$411.50M

Evelo Biosciences has raised a total of $411.50M in funding over 2 rounds. Their latest funding was raised on Dec 16, 2022 from a Post-IPO Debt round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 16, 2022	Post-IPO Debt	$45M	1	Horizon Technology Finance	—	Detail
Jan 29, 2021	Post-IPO Equity	$67.50M	—	—	—	Detail
May 9, 2018	IPO	$85M	—	—	—	Detail
Apr 30, 2018	Series Unknown	$47.50M	1	Dementia Discovery Fund	—	Detail
Feb 22, 2018	Series C	$81.50M	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

4

7

Evelo Biosciences is funded by 7 investors. Horizon Technology Finance and Dementia Discovery Fund are the most recent investors.

Investor Name	Lead Investor	Funding Round
Horizon Technology Finance	Yes	Post-IPO Debt
Dementia Discovery Fund	Yes	Series Unknown
Flagship Pioneering	Yes	Series B
Alexandria Venture Investments	—	Series B
Celgene	—	Series B
GV	—	Series B
Mayo Clinic Ventures	—	Series B